Herpes zoster overview: Natural history and incidence

Journal of the American Osteopathic Association

Volumn 109, Issue 6 SUPPL. 2, 2009, Pages

  Weaver, Bethany A ^a,b  

^a Armor Correctional Health Services   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

CHICKENPOX; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE TRANSMISSION; HERPES ZOSTER; HUMAN; IMMUNIZATION; INCIDENCE; POLYMERASE CHAIN REACTION; POSTHERPETIC NEURALGIA; RISK FACTOR; UNITED STATES; VARICELLA ZOSTER VIRUS;

HERPES ZOSTER; HUMANS; INCIDENCE;

EID: 67650496693     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Gnann Jr JW, Whitley RJ. Clinical practice. Herpes zoster [review]. N Engl J Med. 2002;347:340-346.
2. Marin M, Guris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices (ACIP). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1-40. Available at: http://www.cdc.gov/mmwr/preview /mmwrhtml/rr5604a1.htm. Accessed March 16, 2009.
3. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction [published correction appears in Mayo Clin Proc. 2008; 83:255]. Mayo Clin Proc. 2007;82:1341-1349. Available at: http://www.mayoclinicproceedings.com /content/82/11/1341.long. Accessed March 16, 2009.
4. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30, CE2-4. Available at: http://www.cdc.gov/mmwr /preview/mmwrhtml/rr57e0515a1.htm?s-cid=rr57e0 515-e. Accessed March 11, 2009.
5. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748-753. Available at: http://www.pub medcentral.nih.gov/articlerender. fcgi?tool=pubmed &pubmedid=16050886. Accessed March 16, 2009.
6. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy [review]. Clin J Pain. 2002;18: 350-354.
7. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicellazoster in the aged. Arch Intern Med. 1982;142:291-293.
8. Gnann JW, Whitley RJ. Natural history and treatment of varicella-zoster in high-risk populations. J Hosp Infect. 1991;18(suppl A):317-329.
9. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340-346. Available at: http://content.nejm.org/cgi/content/full/347 /5/340. Accessed April 29, 2009.
10. Gershon AA. Prevention and treatment of VZV infections in patients with HIV. Herpes. 2001;8:32-36. (Pubitemid 32625612)
11. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57:1431-1438. Available at: http: //www3.interscience.wiley.com/cgi-bin/fulltext /117347085/HTMLSTART. Accessed April 29, 2009. (Pubitemid 350308841)
12. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483-1490. (Pubitemid 44880029)
13. Oxman MN. Clinical manifestations of herpes zoster. In: Arvin AM, Gershon AA, eds. Varicella- Zoster Virus: Virology and Clinical Management. Cambridge, England: Cambridge University Press; 2000:246-275.
14. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc. 2009;109(suppl 2):S13-S17.
15. Dobec M, Bossart W, Kaeppeli F, Mueller- Schoop J. Serology and serum DNA detection in shingles. Swiss Med Wkly. 2008;138:47-51. (Pubitemid 351184995)
16. Engelmann I, Petzold DR, Kosinska A, Hepkema BG, Schulz TF, Heim A. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens [published correction appears in J Med Virol. 2008;80:1505; 2008;80:2177]. J Med Virol. 2008;80:467-477. (Pubitemid 351206896)
17. Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med. 1997;157:1217-1224.
18. De Moragas JM, Kierland RR. The outcome of patients with herpes zoster. AMA Arch Derm. 1957;75:193-196.
19. Watson PN, Evans RJ. Postherpetic neuralgia. A review. Arch Neurol. 1986;43:836-840.
20. Kost RG, Straus SE. Postherpetic neuralgia- pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32-42. (Pubitemid 26230812)
21. Katz J, Melzack R. Measurement of pain. Surg Clin North Am. 1999;79:231-252.